ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
September 08, 2021 16:15 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of...
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
September 08, 2021 16:01 ET
|
ProQR Therapeutics N.V.
Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer® RNA editing platformProQR to receive $50 million consisting of upfront...
ProQR to Present at Upcoming Scientific Conferences
November 18, 2019 07:23 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Announces Presentations at the OTS Annual Meeting
September 24, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
May 23, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
April 30, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
April 10, 2018 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing.As an...
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
February 06, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
January 08, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V....
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
October 24, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...